News
Market and company headlines
SLGLAll
Loading
03:00Oct 161 Story
06:00Oct 151 Story
14:00-00:00Oct 142 Stories
Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data
Sol-Gel Technologies (NASDAQ:SLGL) outlined its development and commercialization plans for SGT-610, a topical patidegib treatment being studied to reduce new basal cell carcinomas (BCCs) in patients with Gorlin syndrome, a rare inherited disorder associated with recurrent skin cancers and other man
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day Transcript
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day October 14, 2026 12:00 PM EDTCompany ParticipantsMoshe Arkin - CEO & Executive ChairmanOfer...
02:00-05:00Oct 142 Stories
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
Cantor Fitzgerald Initiates Coverage On Sol-Gel Technologies with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Sol-Gel Technologies (NASDAQ:SLGL) with a Overweight rating.
11:00Oct 81 Story
09:00Sep 301 Story
08:00-10:00Sep 172 Stories
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndromeTop-line results remain on track for late November 2026 NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced that the last patient has completed the last scheduled study visit in the Company's pivo